Quadrant Capital Group LLC Purchases 91 Shares of Abbott Laboratories (NYSE:ABT)

Quadrant Capital Group LLC raised its position in Abbott Laboratories (NYSE:ABT) by 0.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 34,773 shares of the healthcare product maker’s stock after acquiring an additional 91 shares during the period. Quadrant Capital Group LLC’s holdings in Abbott Laboratories were worth $3,933,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ABT. Noble Wealth Management PBC acquired a new position in Abbott Laboratories during the fourth quarter worth $26,000. NewSquare Capital LLC boosted its stake in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock worth $27,000 after buying an additional 105 shares during the last quarter. WealthTrak Capital Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $28,000. Rialto Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $29,000. Finally, Wingate Wealth Advisors Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $34,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ABT shares. The Goldman Sachs Group raised their price target on Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Citigroup increased their price target on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Barclays restated an “overweight” rating and set a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. UBS Group raised their target price on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, January 21st. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $137.94.

Insider Transactions at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $131,123.33. Following the transaction, the executive vice president now owns 74,381 shares in the company, valued at approximately $10,277,222.77. This trade represents a 1.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the sale, the executive vice president now owns 71,928 shares of the company’s stock, valued at approximately $9,625,404.96. This represents a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 116,449 shares of company stock valued at $15,463,316. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $124.46 on Friday. The firm’s 50-day simple moving average is $131.18 and its 200 day simple moving average is $120.84. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The firm has a market cap of $215.85 billion, a price-to-earnings ratio of 16.27, a P/E/G ratio of 2.52 and a beta of 0.80. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.34. The business had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.19 earnings per share. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.90%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s payout ratio is presently 30.85%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.